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S_ary A swine model was developed to study qusantitatively the pharmacokinetics of hepatic extraction
and clearance of doxorubicin (DOX). Systemic and hepatic artery infusions of DOX (0.5-9mg kg-') were
adminstered to 34 pigs. Pharmacokinetic analysis was simplified by use of a double-balloon catheter in the
inferior vena cava to collect hepatic venous effluent. During hepatic artery infusion only, DOX in epatic
venous blood was extracted using activated carbon filters to prevent drug recirculation. Hepatic extraction and
clearance of DOX were independent of dose and route of administration. Extraction ratios varied from 0.75 to
0.91 during hepatic artery infusion and from 0.50 to 0.72 during systemic infusion. Clearance results were
analogous. After cessation of drug infusions, hepatic extraction and clarance of DOX was negative,
suggesting that the liver serves as a drug reservoir during DOX infusion and subsequently is a net source of
unmetabolised drug. Liver extraction and clarance of DOX in pigs are substantial. During either systemic or
hepatic artery infusion of DOX, the liver serves as a drug reservoir. Subsequent mobilisation of this hepatic
pool of DOX may cause prolonged systemic exposure to drug.
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Doxorubicin (DOX), an anthracycline antineoplastic drug, is
one of the most frequently used chemotherapeutic agents.
Much is known about the biochemistry of DOX metabolism.
It is reduced in cellular cytoplasm by aldehyde and ketone
reductases. Detoxification probably occurs by NADPH
cytochrome P450 reductase-catalysed reduction of the oxy-
gen-linked glycoside forms to deoxyglycone forms (Difonzo
et al., 1971; Bachur et al., 1974, 1979; Bachur, 1975; Ben-
jamin et al., 1977; Oki et al., 1977; Felsted and Bachur, 1980;
Gutierrez et al., 1983). DOX and its primary alcohol
metabolite doxorubicinol (DOXOL) are excreted unchanged
in the bile and to a lesser extent in the urine (Difonzo et al.,
1971; Bachur et al., 1974; Bachur, 1975; Benjamin et al.,
1977).
Accurate prediction of acute human clinical toxicity due to
DOX by empirical determination of the plasma phar-
macokinetics of DOX or its metabolites has not proved
feasible (Brenner et al., 1984; Brenner, 1987; Ackland et al.,
1989). Some studies suggest that DOX-induced toxicity cor-
relates with deranged hepatic function as measured by brom-
sulphophthalein time, serum bilirubin concentration or
indocyanine green clearance (Benjamin et al., 1974; Ben-
jamin, 1975; Doroshow and Chan, 1982; Brenner et al.,
1984). Hepatic dysfunction is common in cancer patients
owing to factors such as hepatic metastases, drug-induced
toxicity and viral and bacterial infections. Because DOX may
be used for hepatic artery infusion treatment of hepatocel-
lular carcinoma and neuroendocrne hepatic metastases
(Kobayashi et al., 1986; Moertel, 1987; Kanematsu et al.,
1989; Peletier et al., 1990; Venook et al., 1991; Carr et al.,
1993; Ruszniewski et al., 1993), knowledge of the hepatic
pharmacokinetics of DOX is particularly relevant. Unfor-
tunately, reports concerning the hepatic pharmacokinetics of
doxorubicin are conflicting (Kaye et al., 1985). Although
some investigators have found that hepatic extraction of
DOX is substantial and may be impaired by liver dysfunction
(Garnick et al., 1979; Ballet et al., 1984), others report that
hepatic extraction of DOX is low and pharmacokinetic
parameters are not altered when liver dysfunction is present
(Chan et al., 1980; Brenner et al., 1984, 1987; Preiss et al.,
1987; Munck et al., 1993).
We have developed a swine model to study the phar-
macokinetics of hepatic drug extraction and clearance
(August et al., 1990; 1994). This model permits in vivo
infusion of drug either systemically or to the liver via the
hepatic artery, collection of all hepatic venous effluent and
removal of drug from the effluent before systemic reinfusion.
This is achieved percutaneously with the use of a specially
developed double-balloon catheter, which is positioned in the
inferior vena cava to isolate and collect all hepatic venous
blood. This method avoids the confounding pathophysio-
logical effects of laparotomy and ex vivo perfusion, and
circumvents difficulties associated with sampling blood from
only a single hepatic vein. This paper reports the use of this
model to study hepatic extraction and clearance of DOX.
Materal and Inthos
Hepatic venous isolation/hepatic venous drug extraction
Hepatic venous isolation and hepatic venous drug extraction
were accomplished using a double-balloon catheter in com-
bination with activated charcoal filtration of drug from
hepatic venous effluent. The catheter (Delcath, Stamford, CIT,
USA), a four-lumen, double-balloon, polyethylene catheter,
was inserted through the femoral vein by venous cutdown
(August et al., 1994). Inflation of the caudal balloon superior
to the renal veins and inflation of the cephalad balloon in the
suprahepatic vena cava, just below the right atrium, isolated
all hepatic venous blood (Figure 1). The blood was then
withdrawn through intra-balloon catheter fenestrations into
the main catheter lumen and out to an extracorporeal circuit.
The fourth lumen of the catheter bypassed the main lumen
and allowed blood to flow from the inferior vena cava below
the caudal balloon through the catheter into the suprahepatic
vena cava.
Hepatic venous effluent was circulated through a 1/4-inch
Tygon tubing extracorporeal circuit by a centrifugal cap-
acitance pump (Bio-Medicus model 520 with a BP-50 dis-
posable Bio-pump cartridge; Bio-Medicus, Minneapolis, MN,
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USA) capable of drculating up to 101 of blood per mi.
Extracorporeal flow was monitored with an in-ine flow
tansducer (Bioprobe Transducer model TX20P, Bio-Medi-
cus). In pigs undergoing hepatic artery infusion of DOX, the
effluent was pumped through a pair of paralel, activated
carbon haemoperfusion filters (Diakart, National Medical
Care, Rockleigh, NJ, USA). In pigs receiving DOX via
sstemic infusion, the filters in the extracorporeal circuit were
bypassed. Blood from the circuit was then returned to the pig
via an internal jugular central venous catheter (Figure 1).
The 12 French calbre venous return catheter and a 7 French
carotid artery catheter used for continuous blood pressure
monitoring were placed by cutdown.
Swine andoperativeprocedures
Thirty-four female domestic swine (Hodgin's Kennels,
Howell, MI, USA), weight 20-37 kg, were sudied. All
ecperiments were performed in the morning following a 12 h
fast. Anaesthesia was induced atropine 0.04mgkg-
and either ketamin 1mg kg' and Rompun 2mgkg-'
(Miles, Shawnee Mission, KS) or Telazol 4mgkg-' (Aveco,
Fort Dodge, IA) and Rompun 2 mg kg-'. General anaes-
thesia, with endotracheal intubation and spontaneous ventila-
tion, was m tained using isoflurane. Mean arterial blood
plessure was continuously monitored and maintained above
65 mmHg primarily by infsing lactated Ringer's solution,
30-50ml kg'h-'. Adenalne 0.1-0.3pgkgmin' was
also infused as needed to maintain mean arterial blood pres-
sure, because activated charcoal filters absorb catecholamines
from blood.
Heparin 200 U kg'-I was given by intravenous bolus hourly
starting just before insertion of the double-balloon catheter
to prevent catheter and extacorporeal circuit thrombosis.
For experiments involving hepatic artery infusion of DOX,
an hepatic artery catheter was inserted via femoral artery






Flgwe I Smatc representation of hepatic venous isolation/
hepatic venous drug extraction perfusion crut. Hepatic wenous
effluent was collected by a double-baloon catheter placed within
the inferior vena cava. The blood was circuated through the
extacorporeal cict by a centrifuil capableu
of irculating up to 101 of blood per min Blood flow in the
extracorporeal acrcit (equal to hepatic blood flow) was measured
with an in-lie flow transducer. In pigs that ricdve drug via
hepatic artery infusion, the efliuent was pumped through a pair
of paralle, acfivated carbon baemoperfusion filters and then
retured to the pig via a catheter in the interal jugular vein. In
pigs that rumived drug via pripr infusion, the filters were
omitted from the extracoporea circit.
the proper hepatic artery. If the arerial anatomy prevented
placement of the tip of the catheter beyond the origin of the
gastroduodenal artery while still perfusing the entire liver, the
gstroduodenal artery was angiographically embolised using
a Gelfoam (Upjohn, Kalamazoo, MI, USA) plug. The
double-balloon catheter was inserted by cutdown on the
femoral vein and advanced into the inferior vena cava. Cor-
rect positioning was achieved fluoroscopically.
Hepatic venous isolation was achieved by inflating the
caudal and cephalad balloons ofthe catheter before initiating
drug infusion. The centrifugal pump rate was constantly
monitored and adjusted to pump all hepatic venous effluent
while preventing development of negative pressure sufficient
to collaps the isolated segment of infenor vena cava or the
hepatic veins.
All animals were sacrificed by lethal injection of
Beuthanasia-D (Schering-Plough Animal Health, Kenilworth,
NJ, USA) at completion of each study. At the time of
sacfice, post-mortem examination was performed to ensure
that the hepatic artery and double-balloon catheters were
positioned properly and that no drug extravasation had
occurred.
These studies were approved by the Subcommittee on
Animal Studies of the Ann Arbor Veterans Administration
Medical Center.
Doxorubicin administration
Clinical grade doxorubicin hydrochloride obtained from the
University of Michigan Hospitals in-patient pharmac was
used for all studies. Drug was administered via hepatic artery
infusion to 17 swine and via systemic internal jugular vein
infusion to 17 swine. In groups of three animals, swie
1rived 0.5, 1, 3, 5 or 9mg kg' DOX via either hepatic
artery or systemic vein infusion over 90mm. Hepatic venous
isolation with drug extraction was performed for 240min
after initiation of hepatic artery infusions (time 0-240min).
In swine receiving doxorubicin via systemic infusion, hepatic
venous isolation for 240min using the double-balloon
catheter was performed without hepatic venous drug extrac-
tion (the fites were omitted from the extracorporeal circuit).
This permitted pharmackintic isolation of the liver without
altering systemic distribution of drug.
In all expeimts hepatic venous blood sampls (from the
extracorporeal crcuit before filtration) and sysemic blood
samples were obtained periodically for determination ofdox-
orubicin and metabolite concentrations. In swine undergoing
hepatic artery infusion/hepatic venous drug extaction, blood
sMPle were also obtaied from the extracorporeal circuit
after filtration to determine the efficiency of drug filtration.
Samples were obtained 0, 1, 5, 10, 15, 30, 60 and 90min after
initiation of the drug infusion, and at 91, 95, 100, 105, 120,
150 and 180min after initiation of the infusion (after com-
pletion of the infusion).
Drug analysis
High-pressure liquid chromatography (HPLC)-grade tetra-
hydrofuran and certified-grade ammomum formate, chloro-
form and ammomum sulphate were obtained from Fisher
Laboratories of Allied Industries (Pittsburgh, PA, USA). A
doxorubicinol standard was synthesised according to the
published procedures ofTakanashi and Bachur (1976). Purity
of the doxorubicn and doxorubicinol standards was
confirmed by a single peak on HPLC at published retention
times (Brenner et at., 1985). The lack of other peaks in the
HPLC trace at the sensitivity used suggested at las 95%
purity. Specimens were assayed by HPLC after a chloro-
form-isopropanol (1:1, v/v) extraction according to a
previously published procedure (Brenner et al., 1985). The
technique was modified by the use of a 15cm gBondapak
phenyl column (Waters Associates, Millipore, Milford, MA,
USA) and a Shimadzu fluorescece flow spectrophotometer.
The excitation frequency was 470 nm and emission was
measured at 550nm. These modifications resulted in a lowerlimit of detection of DOX in methanol of 0.0005 nM; the
lower limit of detection of DOX extracted from I ml of
pooled human plasma was 0.005 nM.
Data analysis andpharmacokinetics
Doxorubicin plasma concentrations were calculated, stored,
pharmacokinetically fitted and statistically analysed using
Excel 4.0 (Microsoft, Redmond, WA, USA). KaleidaGraph
(Synergy Software, Reading, PA, USA) was used to display
graphically data and time-concentration curves. The area
under the time-concentration curve (AUC) was integrated
by calculating the sum of the trapezoids formed by data
points between times 0 and 180min, interpolating missing
data, when necessary, using KaleidaGraph.
Hepatic extraction (ER) of DOX was calculated using the
formula:
EH = (Cba- Chl)/Cht
where ChV is the concentration of DOX in the hepatic venous
blood as sampled in the extracorporeal circuit and Cha is the
concentration of DOX in the hepatic artery. In pigs receiving
DOX via systemic infusion or after cessation of either
systemic vein or hepatic arterial infusion, Ch. was assumed to
equal the concentration of DOX as measured in blood sam-
pled from the carotid artery. To calculate Ch. in pigs receiv-
ing DOX via hepatic artery during the infusion, it was
assumed that hepatic artery blood flow (Qh.) was equal to
one-third of the total hepatic blood flow (QH) measured in
the extracorporeal circuit (Gelman et al., 1987; Arvidsson et
al., 1988):
Qh, = 113(QH)
Ch. was then calculated using the formula:
C,. = (DOX infusion rate)/Qb,
Hepatic clearance of DOX (CIH) was calculated using the
formula:
CIH = QH(EH)
In pigs receiving DOX via systemic infusion or after cessa-
tion of either systemic vein or hepatic artery infusion,
Q = QH. During hepatic artery infusion of DOX, Q = Qb. =
1/3(QH). These calculations embody the assumption that,
during hepatic artery infusion of DOX, the contribution of
recirculating DOX to Cb. is negligible because of filtration of
drug from hepatic vein blood by the activated carbon filters.
Mean and standard error of the mean (s.e.m.) of DOX
concentrations, extractions and clearances were calculated by
determining the relevant parameters for each pig individually
and then averaging between pigs receiving the same dose at
the same sampling time.







































Fugwe 2 Time-concentration curves. Typical time-concen-
tration curves plotted for plasma sampled from systemic arterial
blood and hepatic venous blood before filtration. Samples were
also obtained from hepatic venous blood in the extracorporeal
circuit after filtration in pigs receiving doxorubicin via hepatic
artery infusion. Doxorubicin was infused over 90 min (time
0-90). Curves were plotted from mean concentrations (error bars
- s.e.m.s) of three pigs in each group. (a) DOX I mgkg-' via
hepatic artery infusion; (b) DOX I mg kg-' via systemic infusion.
Results
Of the 34 pigs studied, 28 survived until at least 90 min after
cessation of the doxorubicin infusion (t = 180). Two pigs
died from technical problems relating to the experimental
procedures. The remaining four deaths occurred in pigs that
received either 5 mg kg-' (two of five pigs at that dose) or
9 mg kg-' (two of two pigs at that dose) of DOX by systemic
infusion. Post-mortem examination of these pigs demon-
strated stigmata of acute DOX toxicity (pulmonary oedema
and hepatic congestion). In the single pig receiving DOX
9 mgkg-' via systemic infusion in which serum levels were
measured, the systemic AUC at 100 min (just before death)
was 3890gmmin, more than 3-fold higher than any other
AUCs measured in these experiments.
Time-concentration curves (Figure 2)
Time-concentration curves were plotted for each sampling
location at each infusion dose. During hepatic arterial
infusion of DOX with simultaneous hepatic venous drug
extraction in the extracorporeal circuit, hepatic vein drug
concentrations were approximately 2- to 10-fold greater than
those measured systemically at all time points and at all
infusion doses (Figure 2). This was true even after discon-
tinuation of the drug infusion at 90 min. These differences
were not statistically significant. During systemic infusion of
DOX, systemic drug concentrations were consistently 2- to
5-fold greater than those measured in hepatic vein blood.
After the systemic DOX infusion was discontinued, drug
concentrations measured in hepatic vein blood generally ex-
ceeded those observed systemically (Figure 2). Again, these
differences were not statistically significant.
Except in pigs receiving DOX at the 9 mg kg-' dose, DOX
metabolites rarely appeared in hepatic vein blood before
90 min. The metabolite observed most commonly was dox-
orubicinol, at concentrations always less than 5% of simul-
taneous DOX concentrations. Aglycone metabolites were
seen less frequently and at even lower concentrations.~~~~~~~~~~~~~~~~~~I
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Area under tine-concentration curves (AUCs, Figure 3)
Mean AUCs were determined at each sampling location for
each infusion dose by averaging the individual AUCs for
each pig. As expected, AUCs measured in hepatic venous
blood and systemically increased with increasing infusion
dose (Table I). In pigs receiving DOX via hepatic artery
infusion with concurrent hepatic venous drug extraction,
hepatic vein drug exposure was 4- to 10-fold greater than
systemic drug exposure (Figure 3a). In pigs receiving DOX
via systemic infusion, systemic drug exposure exceeded
hepatic vein exposure by a factor of approximately 2 (Figure
3b).
Filter extraction and clearance ofdoxorubicin (Table I)
The filters used for hepatic venous DOX extraction in pigs
receiving drug via hepatic artery infusion were effective.
Filter extraction ratios of DOX ranged from 0.74 to 0.91,
generally exceeded 0.84 between times 0 and 180m, and
did not vary with time or dose.
Hepatic extraction and clearance ofdoxorubicin (Table I)
Hepatic extraction and clearance of DOX in relation to time
















0.5mg kg-l1 mgkg-' 3mg kg-' 5mgkg-'
Doxorubicin infusion dose
9 mg kg-1
Figwe 3 Area under time-concentration curves (AUCs). Dox-
orubicin AUCs were determined from plasma sampled from
systemic arterial blood and hepatic venous blood before filtration.
Samples were also obtained from hepatic venous blood in the
extracorporeal circuit after filtration in pigs receiving doxorubicin
via hepatic artery infusion. AUCs were calculated by summing
the trapezoids formed by actual data points between time 0
(initiation of the doxorubicin infusions) and time 180 min (90 min
after completion of the doxorubicin infusions) in each pig and
then averaging the AUCs within each group. No pigs survived
beyond 105 min in the 9 mgkg-' systemic infusion group. Values
shown are group means (error bars - s.e.m.s). (a) Hepatic artery
infusions; (b) systemic infusions.
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either hepatic artery or systemic infusion of DOX, hepatic
extraction and clarance were positive, nreting hepatic
metabolism and/or distibution of drug. The time-concen-
tration curves suggest that first phase distribution of DOX
was complete by 60min afterinitiation of drug infuion.
Hepatic extraction and clarance of DOX at 60 min during
hepatic artery infusion variedfrom 0.74 to 0.91 and from 5%
to 880 mlmin' respectively; these parameters were not dose
related in the range of doses studied. During systemic
infusion of DOX, extraction and clearanc were somewhat
lower, ranging from 0.50 to 0.72 and from 331 to
560 ml min-' seti, again the parameters did not vary
with dose.
After cessation of DOX infusion, hepatic extraction and
clearance were negative in pigs receiving either hepatic artery
or systemic infusions. This was true at all time points
between 90 and 180 min (0-90 min after completion of the
drug infusion) and at all but the lowest, 0.5 mg kg-', DOX
dose.
The role of the liver in metabolism of DOX is uncertain
(Kaye et at., 1985). This paper reports the use of a new
model of hepatic venous isolation with hepatic venous drug
filtraion to study liver extraction and ckarance of DOX.
The model used in these studies offered a number of advan-
tages. First, the situ hepaticpharmacokinetics of DOX was
studied, avoiding non-physiological conditions present in
models requiring in vitro isolated perfusion of intact livers.
Second, hepatic arterial and venous isolation were accom-
plished without resort to laparotomy, with its attendant
physiologial and pathophysiologil effects (Kestens et al.,
1%1; Skibbaet al., 1983; Schwemmk and Aigner, 1986; van
de Velde et al., 1986; Aigner et al., 1988; Kuet al., 1990, de
Brauw et al., 1991). Third, the hepatic venous isolation
achieved using the double-balloon catheter was complete.
This iid determination ofpharmacokinetc parameters
allowed diret measurement of hepatic blood flow, and
avoided problems of hepatic metabolic inhomogeneity and
laminar flow that may be encountered with models utilising
hepatic vein blood sampling tecniques.
There wer, however, some methoological problems inhe-
rent in this model. Care was taken to m imise their effect on
the experimental resuhs. The model did not permit isolation
or tmesurement of portal venous blood flow to the liver.
This linited the sophisttion of the pma kinetic cal-
culations. While more physioogical than laparotomy-
requiring methods, the technique of hepatic venous isolation
used did necesstate general anahesia and interruption of
the normal path of venous blood return to the heart
Although diverted blood was ultimately retured via the
extracorporeal circuit to the internal jugular vein, a
significant decrease in mean arterial blood pressure was
observed in most animals, requiring infusion of low doses of
adrenaline and vigorous fluid resuscitation. Pigs tolerate
these insults well (August et al., 1994). The infusion of
adrenaline in low doses (0.1-0.3 pgIg-k min-') undoubtedly
altered hepatic vascular reitanw, and possibly altered the
ratio of blood flow between the hepatic artery and the portal
vein (Marinkova et al., 1990). We have, however, previously
demoonsa that hepatic blood flow is stable in pigs under-
going double-balloon catheter hepatic venous isolation and is
apparntly uafected by adeaine, averaging 750-850ml
min' for the duration of the expi ts (August et al.,
1994). The effect of adrenaline on hepatic extraction and
clearance of DOX cannot be determined from these
experments. Fialy, the pcaulations per-
formel for pigs DOX via hepatic artery infusion
assumed that reirculation of DOX through the hepatic
artery and portal vein was minimal because of the presence
of the activated carbon filters in the tracorporeal circuit.
The 74-91% effiency of filtration observed made this
assmption reasonable during the drug infusion phase of the
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experiments when hepatic artery drug concentrations were
high. This assmption, however, was not as well founded
during the post-infusion portion of the studies (time
91-180mi); incomplete filter extraction and physiological
leakage of hepatic venous effluent into the systemic circula-
tion through anatomical pathways exclusive of the hepatic
veins (Skibba and Condon, 1983; Skibba et at., 1983;
Sindelar, 1985) allowed recirculation of some DOX to the
liver via the portal crculation.
The hepatic extraction ratios and hepatic clarances of
DOX measured dffered from those reportedin theliterature
using other model systems. In a study of five patients with
liver metastases from breast cancer and two patients with
carcinoma of the bile duct, Garnicket al. (1979) measured
hepatic extraction of DOX during peripheral infusion of drug
at doses approx ting 1 mg kg-' over 4 h. At 1 h, extrac-
tion ratios were approximately 0.3-0.45. Interestingly, their
data suggest that negtive extraction ratios were measured
within 30 min of discontinuation of the drug infusion. They
did not report extraction ratios for patients receiving hepatic
artery infusions of DOX. Balletet al. (1984) in a study of five
patients wtih hepatocelular carcinoma and either cirrhosis or
chronic hepatitis, found extraction ratios of 0.03-0.105, but
these ratios were measured 20-360min afteradministion
of 35-60mg(m)-l DOX over 5min via pripheral vein.
Although they did not calculate hepatic extraction ratios, the
data that Munck et al. (1993) obtained in a rabbit model
similarly suggest that hepatic clarance of DOX is low. The
higher extraction and ckarance parameters measured in the
current study may reflect species differences and differences in
dosing regimens and routes of administration. Furthermore,
Ganicket al. (1979) and Ballet et al. (1984) studied patients
withliver disease, whereas we studied pigs with normalliver
function. From the available data, the relative contributions
of liver dysfunction and species differences to changes in
hepatic cleaan and extracion of DOX cannot be deter-
mined.
Our data demonstrate negative hepatic eaction and
clarance of DOX fonlowing cessation of either peripheral or
hepatic arteryinfusion of drug. The data suggest that, during
DOX infusion, theliverserves as a reservoir for drug. After
cesation of drug infusion, unmetaboised drug is washed out
of the lver at higher concentrations than drug entering the
lver. Thus, during this washout phase, the lver acts as a net
source of DOX. e experiments do not show where the
intrahatic DOX resevoir reides. Although most DOX in
plasma is bound to plasma proteins (Greene et al., 1983), the
greater affinity of DOX for DNA as opposed to plasma (and,
presumably, other extl r sites) ensues that the bulk of
DOX will initially be found intacdllularly (Myers and
Chabner, 1990). In fact, during the arly distnrbutive phase of
DOX, tise kvels of drug are geneally proportional to their
DNA content (Terasaki et at., 1989). Intercalation of DNA
by DOX is reversible, howver, and as plasma concentrations
of drugdease followingcessation ofinfusions, the equilib-
rium prbably shifts in the dcion of net DOX unb ng
Dffusion and active tansport (possibly by memblane
associated P170-glycoprotein) (Myers and Chabner, 1990) of
DOX out ofhepatocytes may then hlberate free drug into the
systemic circulation.
If the eistence of an intrahepatic reservoir of DOX is
confirmed in humans, there may be important clnical im-
plictions. Following completion of drug infiLsion, hepatic
release of DOX may result in prolonged systemic exposure to
drug. Both the therapeutic and toxic effects of DOX are
thought to be related to systemic AUC (Eichholtz-Wirth,
1980; Legha, 1982: Myers and Chabner, 1990). Therefore,
these data suggat that hepatic pooling of DOX must be
conidered when attempting to optimise DOX efficacy.
Fmally, this study suggts that combination of hepatic
artery infusion of DOX with hepatic venous isolation and
hepatic venous drug extraction may be useful for the treat-
ment of prmary and metasatic tumours in the liver. The
data show that route of ni n had little effect on
hepatic vein DOX AUCs over a range of infusion doses.
OmH-im acdns dezorvbsdo
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Hepatic artery infusion with hepatic venous drug extraction,
however, achieved these hepatic vein AUCs with 5.7- to
23-fold lower systemic exposure than observed during
systemic DOX infusion. It is possible that this phar-
macokinetic benefit may be exploited to take advantage of
the doxorubicin therapeutic dose-response curve in the liver
while avoiding increased systemic exposure.
In summary, these data demonstrate that hepatic extrac-
tion and clearance of DOX during either systemic or hepatic
artery drug infusion in pigs with normal liver function are
higher than previously suspected. Furthermore, during either
systemic or hepatic artery infusion of DOX, the liver serves
as a reservoir for drug. Following completion of drug
infusion. hepatic release of DOX results in prolonged
systemic exposure to drug. Because both therapeutic and
toxic effects of DOX are thought to be related to systemic
AUC, the data suggest that hepatic pooling of DOX must be
considered when attempting to optimise DOX efficacy.
Finally, the pharmacokinetic advantages of hepatic artery
infusion of DOX combined with hepatic venous drug extra-
action may provide sufficient rationale to reconsider regional
DOX administration for the treatment of intrahepatic malig-
nancies.
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